Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
149.66
-2.42 (-1.59%)
Apr 16, 2026, 11:55 AM EDT - Market open
Novartis AG Revenue
In the year 2025, Novartis AG had annual revenue of $56.67B with 9.57% growth. Novartis AG had revenue of $13.86B in the quarter ending December 31, 2025, with 2.23% growth.
Revenue (ttm)
$56.67B
Revenue Growth
+9.57%
P/S Ratio
5.10
Revenue / Employee
$752,973
Employees
75,267
Market Cap
289.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.67B | 4.95B | 9.57% |
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | -46.22B | -48.09% |
| Dec 31, 2019 | 96.12B | 5.27B | 5.80% |
| Dec 31, 2018 | 90.85B | 5.11B | 5.96% |
| Dec 31, 2017 | 85.74B | -12.21B | -12.47% |
| Dec 31, 2016 | 97.95B | -1.85B | -1.85% |
| Dec 31, 2015 | 99.80B | -6.01B | -5.68% |
| Dec 31, 2014 | 105.81B | 1.23B | 1.18% |
| Dec 31, 2013 | 104.59B | 1.53B | 1.49% |
| Dec 31, 2012 | 103.05B | 43.68B | 73.56% |
| Dec 31, 2011 | 59.38B | 7.81B | 15.15% |
| Dec 31, 2010 | 51.56B | 6.46B | 14.32% |
| Dec 31, 2009 | 45.10B | 2.52B | 5.92% |
| Dec 31, 2008 | 42.58B | 3.64B | 9.34% |
| Dec 31, 2007 | 38.95B | 3.84B | 10.94% |
| Dec 31, 2006 | 35.11B | 5.35B | 17.99% |
| Dec 31, 2005 | 29.75B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
NVS News
- 1 day ago - Instem Taps ex-Novartis Head of Emerging Technologies to Put Science Behind Practical AI and NAMs - Business Wire
- 1 day ago - Big Pharma Deepens AI Ties. What It Means For Novo, Novartis. - Investor's Business Daily
- 1 day ago - Anthropic Expands Board with Novartis CEO Amid IPO Plans - GuruFocus
- 2 days ago - Novartis Partners with OpenAI to Enhance AI Integration in Pharma - GuruFocus
- 2 days ago - Anthropic Adds Novartis CEO to Board - WSJ
- 7 days ago - Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030 - GlobeNewsWire
- 9 days ago - PPH, NVS, SNY, NVO: ETF Outflow Alert - Nasdaq
- 16 days ago - Novartis (NVS) Reports Promising Phase III Results for Fabhalta in IgA Nephropathy - GuruFocus